|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...7576777879808182838485...156157» |
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: FasT: Observation of Treatment With Certolizumab Pegol in Daily Practice (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=1117, Completed, Sponsor: UCB Pharma
Active, not recruiting --> Completed
- |||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial primary completion date: COMP-ACT: A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX (clinicaltrials.gov) - Jan 13, 2015
P3, N=600, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Oct 2016 --> Feb 2016
- || Trial primary completion date: REACTIV: Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis (clinicaltrials.gov) - Jan 13, 2015
P=N/A, N=75, Recruiting, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Oct 2016 --> Feb 2016 Trial primary completion date: Sep 2014 --> Jul 2015
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open, Enrollment change: U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497) (clinicaltrials.gov) - Jan 13, 2015
P=N/A, N=300, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2014 --> Jul 2015 Active, not recruiting --> Recruiting | N=160 --> 300
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open, Enrollment change, Trial primary completion date: An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 13, 2015
P=N/A, N=250, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting | N=160 --> 300 Terminated --> Recruiting | N=95 --> 250 | Trial primary completion date: Mar 2012 --> Dec 2015
- glutathione PEGylated liposomal methylprednisolone (ENX-201) / BBB Therap, TTY Biopharm
Clinical: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients (clinicaltrials.gov) - Jan 13, 2015
P1, N=54, Active, not recruiting, Sponsor: BBB-Therapeutics B.V.
Terminated --> Recruiting | N=95 --> 250 | Trial primary completion date: Mar 2012 --> Dec 2015 Recruiting --> Active, not recruiting
- andecaliximab (GS-5745) / Gilead
P1 data, PK/PD data, Trial primary completion date: Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 12, 2015
P1, N=20, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Mar 2015
- Trial primary completion date: Multi-Colored Placido Disk Viability (clinicaltrials.gov) - Jan 12, 2015
P=N/A, N=20, Recruiting, Sponsor: University of Rochester
Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: Jul 2014 --> Sep 2015
- ||| Benlysta (belimumab) / GSK
Trial initiation date: A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector (clinicaltrials.gov) - Jan 9, 2015
P2b, N=100, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Jul 2014 --> Sep 2015 Initiation date: May 2014 --> Jan 2014
- | Enrollment open: Comparison of Treatments Following Total Knee Replacement (clinicaltrials.gov) - Jan 8, 2015
P3, N=240, Recruiting, Sponsor: University of Pittsburgh
Initiation date: May 2014 --> Jan 2014 Not yet recruiting --> Recruiting
- Enrollment open, Trial initiation date, Trial primary completion date: IMMUNOSEP: Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients (clinicaltrials.gov) - Jan 8, 2015
P=N/A, N=30, Recruiting, Sponsor: University Hospital, Bordeaux
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014 | Trial primary completion date: Dec 2015 --> May 2016
- |||| Extavia (IFN-β-1b) / Novartis
Trial completion, Enrollment change, Trial primary completion date: EPOC: Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change (clinicaltrials.gov) - Jan 8, 2015
P4, N=62, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014 | Trial primary completion date: Dec 2015 --> May 2016 Recruiting --> Completed | N=200 --> 62 | Trial primary completion date: Sep 2014 --> Jun 2014
- dexamethasone / Generic mfg., prednisone / Generic mfg.
New P3 trial: EIS2002: Daily Prednisone Versus Pulsed Dexamethasone in Treatment-na (clinicaltrials.gov) - Jan 8, 2015
P3, N=26, Completed, Sponsor: University Hospital, Essen
- | prezalumab (AMG 557) / Amgen, AstraZeneca
New P2 trial: A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sj (clinicaltrials.gov) - Jan 8, 2015
P2, N=42, Not yet recruiting, Sponsor: MedImmune LLC
- Baqsimi (glucagon intranasal dry powder) / Amphastar
Enrollment closed, Trial primary completion date: Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Jan 8, 2015
P2/3, N=48, Active, not recruiting, Sponsor: T1D Exchange Clinic Network Coordinating Center
Recruiting --> Completed | N=200 --> 62 | Trial primary completion date: Sep 2014 --> Jun 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Jan 2015
- || BI 655064 / AbbVie, Boehringer Ingelheim
Enrollment closed: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy (clinicaltrials.gov) - Jan 8, 2015
P1, N=106, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Jan 2015 Recruiting --> Active, not recruiting
- |||| Lemtrada (alemtuzumab) / Sanofi
Trial completion: A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif (clinicaltrials.gov) - Jan 8, 2015
P2, N=334, Completed, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Biomarker, Enrollment change, Trial termination, Trial primary completion date: USPIO-CIS: The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System. (clinicaltrials.gov) - Jan 7, 2015
P=N/A, N=37, Terminated, Sponsor: Rennes University Hospital
Active, not recruiting --> Completed N=50 --> 37 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Jun 2014; terminated ( Halted prematurely,expiration of investigationnal product)
- || Enrollment change: Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty (clinicaltrials.gov) - Jan 7, 2015
P=N/A, N=120, Recruiting, Sponsor: Zimmer, Inc.
N=50 --> 37 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Jun 2014; terminated ( Halted prematurely,expiration of investigationnal product) N=200 --> 120
- Trial primary completion date: SIGNS: Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study (clinicaltrials.gov) - Jan 7, 2015
P=N/A, N=704, Recruiting, Sponsor: Technische Universit
N=200 --> 120 Trial primary completion date: Dec 2015 --> Dec 2016
- || Enrollment status: Threshold Suspend in Pediatrics at Home (clinicaltrials.gov) - Jan 7, 2015
P=N/A, N=300, Enrolling by invitation, Sponsor: Medtronic Diabetes
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Enrolling by invitation
- | Tavneos (avacopan) / Kissei, Amgen, Otsuka
Enrollment open: Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis (clinicaltrials.gov) - Jan 7, 2015
P2, N=45, Recruiting, Sponsor: ChemoCentryx
Recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- | SAR113244 / Sanofi
New P1 trial: Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients (clinicaltrials.gov) - Jan 6, 2015
P1, N=24, Not yet recruiting, Sponsor: Sanofi
- || CNTO6785 / J&J, Fontacea
Trial primary completion date: An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Jan 5, 2015
P2, N=250, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2014 --> Jun 2015
- | staphylococcal protein A (PRTX-100) / Protalex
New P1/2 trial, P1/2 data, IO biomarker: SPARTA-II: 6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection (clinicaltrials.gov) - Jan 5, 2015
P1/2, N=20, Not yet recruiting, Sponsor: Protalex, Inc.
- Trial initiation date, Trial primary completion date: Diabeto-SMS: Text Message for Adolescents With Poorly Controlled Type 1 Diabetes (clinicaltrials.gov) - Jan 5, 2015
P=N/A, N=100, Not yet recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Nov 2014 --> Jun 2015 Initiation date: Sep 2014 --> Jan 2015 | Trial primary completion date: Dec 2015 --> Apr 2016
- Trial completion: The Effect of Guided Imagery in Children With Type 1 Diabetes Mellitus on Glucose Levels and on Glycemic Control (clinicaltrials.gov) - Jan 5, 2015
P=N/A, N=13, Completed, Sponsor: Assaf-Harofeh Medical Center
Initiation date: Sep 2014 --> Jan 2015 | Trial primary completion date: Dec 2015 --> Apr 2016 Not yet recruiting --> Completed
- Adherence: ADELES: Effectiveness of Pharmaceutical Care in the Adherence of Systemic Lupus Erythematosus Treatment (clinicaltrials.gov) - Jan 2, 2015
P=N/A, N=120, Recruiting, Sponsor: Oswaldo Cruz Foundation
- ||||| Plivensia (sirukumab) / J&J
Enrollment closed: A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) (clinicaltrials.gov) - Jan 2, 2015
P3, N=878, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- ARG-301 / arGentis
Trial primary completion date: Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Jan 2, 2015
P1, N=32, Recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2014 --> Sep 2015
- | ramipril / Generic mfg.
Enrollment change, Trial primary completion date: PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease) (clinicaltrials.gov) - Jan 2, 2015
P3, N=65, Terminated, Sponsor: Northwestern University
Trial primary completion date: Oct 2014 --> Sep 2015 N=373 --> 65 | Trial primary completion date: Sep 2013 --> Jun 2010
- ||| Betaseron (IFN-?-1b) / Bayer
Enrollment change: An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS (clinicaltrials.gov) - Jan 2, 2015
P4, N=271, Completed, Sponsor: Bayer
N=373 --> 65 | Trial primary completion date: Sep 2013 --> Jun 2010 N=400 --> 271
- | Januvia (sitagliptin) / Merck (MSD)
New P1 trial: Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop (clinicaltrials.gov) - Jan 2, 2015
P1, N=17, Recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
- ||| azathioprine / Generic mfg.
Enrollment closed, Trial primary completion date: Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (clinicaltrials.gov) - Jan 2, 2015
P4, N=180, Active, not recruiting, Sponsor: University Medical Centre Groningen
N=400 --> 271 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Jun 2014
- Trial primary completion date: An Internet-based Self-management Program for Adolescents With Arthritis (clinicaltrials.gov) - Dec 30, 2014
P=N/A, N=294, Recruiting, Sponsor: The Hospital for Sick Children
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Jun 2014 Trial primary completion date: Mar 2015 --> Mar 2016
- New P1 trial: Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis (clinicaltrials.gov) - Dec 30, 2014
P1, N=100, Recruiting, Sponsor: American CryoStem Corporation
- Trial completion, Enrollment change: A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1 (clinicaltrials.gov) - Dec 30, 2014
P2, N=18, Completed, Sponsor: Profil Institut f
Trial primary completion date: Mar 2015 --> Mar 2016 Active, not recruiting --> Completed | N=13 --> 18
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial primary completion date, Monotherapy: An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (clinicaltrials.gov) - Dec 30, 2014
P=N/A, N=608, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | N=13 --> 18 Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Sep 2014
- | enoxaparin sodium / Generic mfg.
New P4 trial: Timing of Initiation of LMWH Administration in Pregnant Women With APS (clinicaltrials.gov) - Dec 29, 2014
P4, N=150, Recruiting, Sponsor: Mohamed Sayed Abdelhafez
- |||| Benlysta (belimumab) / GSK
Trial primary completion date: BLISS-SC: A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Dec 25, 2014
P3, N=816, Active, not recruiting, Sponsor: Human Genome Sciences Inc., a GSK Company
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Sep 2014 Trial primary completion date: Oct 2014 --> Feb 2015
- methylprednisolone oral / Generic mfg.
Clinical: Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse (clinicaltrials.gov) - Dec 25, 2014
P4, N=28, Recruiting, Sponsor: Germans Trias i Pujol Hospital
Trial primary completion date: Oct 2014 --> Feb 2015 N=48 --> 28
- | Phase classification: Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents (clinicaltrials.gov) - Dec 25, 2014
P4, N=144, Recruiting, Sponsor: Pfizer
N=48 --> 28 Phase classification: P=N/A --> P4
- Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche
Trial termination: A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate (clinicaltrials.gov) - Dec 25, 2014
P2, N=24, Terminated, Sponsor: Hoffmann-La Roche
Phase classification: P=N/A --> P4 Completed --> Terminated; The study was terminated early because of a related decision to stop the development of ocrelizumab in rheumatoid arthritis.
- Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change, Trial termination, Trial primary completion date: An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 25, 2014
P=N/A, N=95, Terminated, Sponsor: Hoffmann-La Roche
Completed --> Terminated; The study was terminated early because of a related decision to stop the development of ocrelizumab in rheumatoid arthritis. N=250 --> 95 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Mar 2012; Contract terminated with Site Management Organization
- || Enbrel (etanercept) / Pfizer, Amgen
Enrollment status, Phase classification: REACH RA: Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice (clinicaltrials.gov) - Dec 25, 2014
P4, N=140, Recruiting, Sponsor: Pfizer
N=250 --> 95 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Mar 2012; Contract terminated with Site Management Organization Enrolling by invitation --> Recruiting | Phase classification: PN/A --> P4
- ||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed: A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis. (clinicaltrials.gov) - Dec 25, 2014
P3, N=101, Active, not recruiting, Sponsor: Hoffmann-La Roche
Enrolling by invitation --> Recruiting | Phase classification: PN/A --> P4 Recruiting --> Active, not recruiting
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed, Enrollment change: U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497) (clinicaltrials.gov) - Dec 25, 2014
P=N/A, N=160, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=300 --> 160
- ||| Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent (clinicaltrials.gov) - Dec 25, 2014
P=N/A, N=505, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=300 --> 160 Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Sep 2014
- ||||| Cyltezo (adalimumab biosimilar) / Boehringer Ingelheim
Trial initiation date: VOLTAIRE-RA: BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 24, 2014
P3, N=650, Not yet recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Sep 2014 Initiation date: Jun 2014 --> Jan 2015
- ||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment change, Trial primary completion date: COMP-ACT: A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX (clinicaltrials.gov) - Dec 24, 2014
P3, N=730, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Jun 2014 --> Jan 2015 N=600 --> 730 | Trial primary completion date: Feb 2016 --> Oct 2016